Bradley A J, Breen J E, Payne B, White V, Green M J
Quality Milk Management Services Ltd., Cedar Barn, Easton Hill, Easton, Nr Wells, Somerset, BA5 1DU, United Kingdom; University of Nottingham, School of Veterinary Medicine and Science, Sutton Bonington Campus, Sutton Bonington, Leicestershire, LE12 5RD, United Kingdom.
Quality Milk Management Services Ltd., Cedar Barn, Easton Hill, Easton, Nr Wells, Somerset, BA5 1DU, United Kingdom; University of Nottingham, School of Veterinary Medicine and Science, Sutton Bonington Campus, Sutton Bonington, Leicestershire, LE12 5RD, United Kingdom.
J Dairy Sci. 2015 Mar;98(3):1706-20. doi: 10.3168/jds.2014-8332. Epub 2014 Dec 18.
Vaccination can play a useful role in mastitis control programs, although there is a relative dearth of large, well-controlled field efficacy studies. This paper presents the findings on the use of a commercially available vaccine (Startvac, Hipra UK Ltd., Nottingham, UK) on commercial units under UK field conditions. In total, 3,130 cows were recruited from 7 farms and were randomly allocated, within farm, to 1 of 3 groups. The first group received the vaccine following the label regimen, the second group was vaccinated every 90 d following an initial vaccination course, and the third group was left unvaccinated to act as controls. Vaccine efficacy was assessed in the first 120 d of lactation. Data were available for analysis from 1,696 lactations in 1,549 cows. In total, 779 cases of clinical mastitis occurred in the 3 study groups, and we detected no significant difference in the incidence or prevalence of clinical or subclinical mastitis between any of the 3 groups. Mastitis vaccination following the label regimen was associated with a significant reduction in the severity of clinical cases. Cows in this group were at significantly decreased odds of developing clinical mastitis presenting with more than just milk changes [odds ratio: 0.58; 95% confidence interval (CI): 0.35-0.98]. Similarly, each additional vaccination resulted in a cow being at decreased odds of developing clinical mastitis presenting with more than just milk changes (odds ratio: 0.87; 95% CI: 0.77-0.98). Although no cows were culled because of severe mastitis in either of the vaccinated groups, we detected no significant difference in the mastitis-related culling rate between groups. Analysis of milk production data demonstrated that, on average, cows on the label regimen produced a higher volume of milk (231 L; 95% CI: 104.1-357.4) and more milk solids (12.36 kg; 95% CI: 3.12-21.60) than unvaccinated cows in the first 120 d of lactation. Conservative analysis suggested that a return on investment of 2.57:1 could be expected under UK conditions based on increased milk yield alone.
疫苗接种在乳腺炎防控计划中可发挥有益作用,尽管大型、严格对照的现场有效性研究相对较少。本文介绍了在英国现场条件下,在商业养殖场使用一种市售疫苗(Startvac,英国希普拉有限公司,诺丁汉,英国)的研究结果。总共从7个农场招募了3130头奶牛,并在农场内随机分配到3组中的1组。第一组按照标签方案接种疫苗,第二组在初次接种疫苗后每90天接种一次,第三组不接种作为对照。在泌乳的前120天评估疫苗效力。有1549头奶牛的1696次泌乳数据可供分析。3个研究组总共发生了779例临床乳腺炎病例,我们在3组中的任何一组之间均未检测到临床或亚临床乳腺炎的发病率或患病率存在显著差异。按照标签方案进行乳腺炎疫苗接种与临床病例严重程度的显著降低相关。该组奶牛发生不仅仅是乳汁变化的临床乳腺炎的几率显著降低[比值比:0.58;95%置信区间(CI):0.35 - 0.98]。同样,每额外接种一次,奶牛发生不仅仅是乳汁变化的临床乳腺炎的几率就会降低(比值比:0.87;95%CI:0.77 - 0.98)。尽管在两个接种组中均没有奶牛因严重乳腺炎而被淘汰,但我们在组间未检测到乳腺炎相关淘汰率的显著差异。对产奶数据的分析表明,平均而言,在泌乳的前120天,按照标签方案接种的奶牛比未接种的奶牛产奶量更高(231升;95%CI:104.1 - 357.4),乳固体更多(12.36千克;95%CI:3.12 - 21.60)。保守分析表明,仅基于产奶量的增加,在英国条件下预计投资回报率为2.57:1。